FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.

Expert Panel Shift Reflects Peptide Industry’s Influence on FDA Review Process

FDA panel on peptides will include – Next month, U.S. health officials will convene to reassess a list of contentious peptide drugs, a decision that marks a significant shift in the composition of the advisory panel overseeing the matter. Among those set to contribute to the discussion will be physicians and pharmacists with substantial financial investments in the rapidly expanding market for unproven therapeutic compounds. The Food and Drug Administration (FDA) announced the list of participants on Monday, revealing that the upcoming meeting will feature a mix of practitioners directly involved in the promotion and distribution of these substances. This change contrasts with earlier panels, which were dominated by academic researchers and university-based experts.

Reconsideration of Peptide Safety and Efficacy

The two-day session focuses on evaluating the safety and effectiveness of several widely used peptide injections, some of which have garnered support from Health Secretary Robert F. Kennedy Jr. Kennedy’s advocacy has been instrumental in shaping the agenda, aligning it with the goals of the Make America Healthy Again movement. This initiative, which has gained traction in recent years, seeks to streamline regulatory processes and prioritize alternative therapies, including peptides, in public health discourse. While the FDA has long maintained a cautious stance on these substances, the new panel reflects a broader push to integrate industry perspectives into the evaluation framework.

Peptides, such as BPC-157 and TB-500, have become a staple in wellness trends among athletes, influencers, and celebrities. Despite their popularity, these compounds are often marketed with vague claims about muscle building, injury recovery, and anti-aging benefits. Critics argue that such assertions lack rigorous scientific backing, yet their appeal continues to grow. The FDA’s recent decision to include practitioners with vested interests in the peptide industry underscores a potential conflict of interest, as these experts may advocate for substances that have not undergone extensive human trials.

The Regulatory Labyrinth of Peptide Therapies

The FDA’s role in regulating peptides has been a subject of debate, particularly regarding the use of “research use only” labels to bypass stricter oversight. This designation allows peptide sellers to operate with fewer restrictions, as the agency does not regulate research chemicals in the same way it does pharmaceuticals. Compounding pharmacies, which customize medications not available through standard drug manufacturers, play a key role in distributing these products. Many of these injectable peptides are sold online and promoted in wellness clinics, often without clear evidence of their therapeutic benefits.

Industry advocates claim that these unapproved therapies offer personalized health solutions, but pharmaceutical experts counter that their use is akin to self-regulation in a loosely governed market. The “Wild West” of peptide therapy, as it has been dubbed, is experiencing rapid growth. The upcoming FDA meeting is part of a larger effort to determine whether this trend should be embraced or curtailed. Previous panels, composed largely of university-affiliated researchers, had frequently voted against peptide ingredients proposed by compounding pharmacies, citing insufficient data to support their use in patients.

Panel Members with Industry Ties

Among the new participants is Dr. Haleem Mohammed, a Florida-based practitioner who operates clinics under the Gameday Men’s Health umbrella. His services include peptide injections alongside vitamin infusions and testosterone treatments. The company’s website explicitly states that its compounded medications are not FDA-approved, and the agency does not verify their safety. This aligns with the broader industry narrative that traditional regulatory frameworks are too rigid for innovative therapies.

“Compounded medications offered through our services are not FDA-approved, and the FDA does not verify their safety.” — Gameday Men’s Health website

Another panelist, Dr. Gabriel Alizaidy, charges $500 for “peptide and hormone” consultations. His online presence on platforms like Instagram and TikTok highlights his influence in promoting substances such as BPC-157 and GHK-Cu to a large audience. Alizaidy’s disclaimer emphasizes that his services are educational, not medical, stating: “Each consultation is educational in nature and does not constitute medical care, diagnosis, or treatment.” This raises questions about the balance between patient guidance and commercial promotion within the FDA review process.

Bobby Harshbarger, a Tennessee state senator and pharmacist, adds a political dimension to the panel. His family’s pharmacy, Premiere Pharmacy, specializes in compounded medications targeting weight loss, longevity, and pain management. Harshbarger’s mother, Rep. Diana Harshbarger, is also a pharmacist and a Republican representative from Tennessee. Last year, she authored a letter to Kennedy urging the relaxation of FDA restrictions on six peptides, a move that reflects the political lobbying efforts of industry stakeholders.

The Harshbarger family’s ties to the peptide movement extend beyond policy. In 2024, Robert Harshbarger Jr., Diana’s husband, was pardoned by former President Donald Trump for a crime involving the substitution of an unapproved Chinese drug for a standard treatment in kidney dialysis patients. He had pleaded guilty over a decade earlier and served a four-year prison sentence after losing his pharmacy license. This episode underscores the intersection of regulatory oversight and political influence in the peptide industry.

Global Perspectives and Doping Concerns

While the FDA is reevaluating these substances, international sports organizations have classified BPC-157 and TB-500 as doping agents. This designation highlights concerns about their potential misuse in competitive athletics, where they may provide an unfair advantage. The seven peptides under review in July represent a growing list of compounds that have entered the mainstream without comprehensive clinical trials. As the meeting unfolds, the focus will remain on whether the FDA’s new approach balances innovation with patient safety.

Experts warn that the current regulatory environment allows for significant risks, as many peptide products are not subject to the same scrutiny as FDA-approved medications. The inclusion of practitioners who promote these substances in the advisory process may lead to a more lenient evaluation, potentially paving the way for broader use in the U.S. Despite the controversy, the peptide industry continues to thrive, driven by consumer demand and a growing network of clinics and online retailers. The outcome of the FDA’s meeting could shape the future of these unproven therapies, determining whether they will be embraced as the next frontier in health care or reclassified as risky supplements.

As the panel deliberates, the question remains: how will the agency reconcile its mandate to protect public health with the push for deregulation? The decision will likely reflect the broader tensions between scientific rigor and industry advocacy, a dynamic that has defined the evolution of peptide therapy in the U.S. market. With the meeting serving as a pivotal moment, the FDA’s stance may influence both the regulatory landscape and the public’s perception of these controversial compounds.